| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Vemircopan | ACH-0145228; ACH-5228; ALXN-2050 | Phase 1 Clinical | Achillion Pharmaceuticals Inc | Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Hepatic Insufficiency; Lupus Nephritis; Myasthenia Gravis; Renal Insufficiency | Details |
| ACH-5548 | ACH-5548; ACH-0145548 | Phase 1 Clinical | Achillion Pharmaceuticals Inc | Autoimmune Diseases | Details |
| BCX-9930 | BCX-9930 | Phase 1 Clinical | Biocryst Pharmaceuticals Inc | C3 glomerulopathy; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Hemoglobinuria, Paroxysmal | Details |
| BCX-10013 | BCX-10013 | Phase 1 Clinical | Biocryst Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
| Zoracopan | ALXN-2080 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Danicopan | ACH-4471; ACH-0144471; ACH-CFDIS; ALXN-2040 | Approved | Achillion Pharmaceuticals Inc | VOYDEYA, Voydeya | Japan | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2024-01-18 | C3 glomerulopathy; Coronavirus Disease 2019 (COVID-19); Geographic Atrophy; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Hemolysis; Hepatic Insufficiency | Details |